SEPS PHARMA -  

Ranking results:

Past rankings:

Ranking timeline:

Project Participation Performance(2010-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2021 0 3.533.108 256.320 1
2017 0 5.999.179 373.125 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
ALAN BOYD CONSULTANTS LIMITED1
ASTRAZENECA1
COMMISSARIAT A L'ENERGIE ATOMIQUE1
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER1
EUROPEAN RESEARCH SERVICES1
HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG1
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE1
JANSSEN PHARMACEUTICA NV1
KATHOLIEKE UNIVERSITEIT LEUVEN1
LABORATOIRES MAYOLY SPINDLER1
NANOIMMUNOTECH SL1
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS1
PRODIGEST1
SCIENSEED SL1
SPARKS & CO1
UNIVERSITA DEGLI STUDI DI PARMA1
UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY OF IRELAND CORK1
UNIVERSITY COLLEGE LONDON1
UNIVERSITY OF COPENHAGEN1
UPPSALA UNIVERSITET1

Constancy:

Total number of partners: 20
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 20
Frequent / Rare Partner Ratio: 0

Project overview:

Start dateProjectacronymrolefundingpartners
2021-01-01Boosting advanced doctoral training in innovative colon targeting drugs COLOTANparticipant3.533.10810
2017-01-01New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting Janus kinases NEW DEALparticipant5.999.17912